{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:58:04Z","timestamp":1773061084960,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015652","name":"Barts Charity","doi-asserted-by":"publisher","award":["MGU0284"],"award-info":[{"award-number":["MGU0284"]}],"id":[{"id":"10.13039\/100015652","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ahj.2024.06.001","type":"journal-article","created":{"date-parts":[[2024,6,9]],"date-time":"2024-06-09T13:51:10Z","timestamp":1717941070000},"page":"96-104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["REGENERATE-COBRA: A phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina"],"prefix":"10.1016","volume":"275","author":[{"given":"Rohini","family":"Ramaseshan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanuka","family":"Perera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mervyn","family":"Andiapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cono","family":"Ariti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Kelham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7941-9653","authenticated-orcid":false,"given":"Anthony","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2024.06.001_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCRESAHA.118.314118","article-title":"The impact of cell therapy on cardiovascular outcomes in patients with refractory angina","volume":"124","author":"Jones","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2024.06.001_bib0002","doi-asserted-by":"crossref","first-page":"709705","DOI":"10.3389\/fcvm.2021.709795","article-title":"Son of a lesser god: the case of cell therapy for refractory angina","volume":"8","author":"Bassetti","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0003","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1093\/eurheartj\/eht165","article-title":"Long-term survival in patients with refractory angina","volume":"34","author":"Henry","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/eurheartj\/ehaa820","article-title":"Management of refractory angina: an update","volume":"42","author":"Davies","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001287","article-title":"Predictors of long-term clinical endpoints in patients with refractory angina","volume":"4","author":"Povsic","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ahj.2024.06.001_bib0006","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1001\/jama.2009.685","article-title":"Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial","volume":"301","author":"Van Ramshorst","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.06.001_bib0007","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1161\/CIRCRESAHA.115.303463","article-title":"Selected CD133+ progenitor cells to promote angiogenesis in patients with refractory angina final results of the PROGENITOR randomized trial","volume":"115","author":"Jimenez-Quevedo","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2024.06.001_bib0008","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2016.05.003","article-title":"The RENEW trial: efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina","volume":"9","author":"Povsic","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.06.001_bib0009","doi-asserted-by":"crossref","first-page":"521","DOI":"10.5603\/CJ.2018.0082","article-title":"Effects of trans-endocardial delivery of bone marrow-derived CD133+ cells on angina and quality of life in patients with refractory angina: a sub-analysis of the REGENT-VSEL trial","volume":"25","author":"Jadczyk","year":"2018","journal-title":"Cardiol J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-018-0969-z","article-title":"Linking cell function with perfusion: insights from the transcatheter delivery of bone marrow-derived CD133+ cells in ischemic refractory cardiomyopathy trial (RECARDIO)","volume":"9","author":"Bassetti","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ahj.2024.06.001_bib0011","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ijcard.2013.10.079","article-title":"Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina \u2014 final 3-year follow-up","volume":"170","author":"Mathiasen","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ahj.2024.06.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2014.03.022","article-title":"Adipose-derived regenerative cells in patients with ischemic cardiomyopathy: the PRECISE Trial","volume":"168","author":"Perin","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/5556800","article-title":"Functional recovery after intramyocardial injection of adipose-derived stromal cells assessed by cardiac magnetic resonance imaging","volume":"2021","author":"Konstanty-Kalandyk","year":"2021","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.ahj.2024.06.001_bib0014","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-019-2110-1","article-title":"Autologous adipose-derived stromal cell treatment for patients with refractory angina (MyStromalCell Trial): 3-years follow-up results","volume":"17","author":"Qayyum","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0015","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1093\/eurheartj\/ehm485","article-title":"Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial)","volume":"28","author":"Tse","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0016","doi-asserted-by":"crossref","DOI":"10.1159\/000320217","article-title":"Intracoronary autologous CD34+ Stem cell therapy for intractable angina","volume":"117","author":"Wang","year":"2010","journal-title":"Cardiology"},{"key":"10.1016\/j.ahj.2024.06.001_bib0017","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2024.06.001_bib0018","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.3727\/096368916X691484","article-title":"Autologous CD34+ cell therapy for refractory angina: 2-year outcomes from the ACT34-CMI study","volume":"25","author":"Henry","year":"2016","journal-title":"Cell Transplant"},{"key":"10.1016\/j.ahj.2024.06.001_bib0019","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/ccd.26601","article-title":"The Athena trials: autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction","volume":"89","author":"Henry","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.ahj.2024.06.001_bib0020","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/clc.22922","article-title":"A comprehensive meta-analysis of stem cell therapy for chronic angina","volume":"41","author":"Shah","year":"2018","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ahj.2024.06.001_bib0021","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1161\/CIRCRESAHA.115.308056","article-title":"Impact of cell therapy on myocardial perfusion and cardiovascular outcomes in patients with angina refractory to medical therapy: a systematic review and meta-analysis","volume":"118","author":"Khan","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2024.06.001_bib0022","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/sctm.20-0046","article-title":"CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina","volume":"9","author":"Johnson","year":"2020","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0023","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1093\/eurheartj\/ehx764","article-title":"Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials","volume":"39","author":"Henry","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0024","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/rme-2022-0138","article-title":"Cell administration routes for heart failure: a comparative re-evaluation of the REGENERATE-DCM and REGENERATE-IHD trials","volume":"17","author":"Sim","year":"2022","journal-title":"Regenerative Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0025","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1161\/CIRCULATIONAHA.112.000230","article-title":"Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy","volume":"128","author":"Vrtovec","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.06.001_bib0026","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s13287-021-02667-1","article-title":"Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials","volume":"12","author":"Attar","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.ahj.2024.06.001_bib0027","first-page":"1465","article-title":"Stem cell therapy for chronic ischaemic heart disease and congestive heart failure","volume":"12","author":"Fisher","year":"2016","journal-title":"CDSR"},{"key":"10.1016\/j.ahj.2024.06.001_bib0028","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1097\/CCM.0000000000001138","article-title":"Intracoronary transfusion of circulation-derived CD34+ cells improves left ventricular function in patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention","volume":"43","author":"Lee","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0029","first-page":"506","article-title":"Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy","volume":"3","author":"Adler","year":"2011","journal-title":"Front Biosci - Elite"},{"key":"10.1016\/j.ahj.2024.06.001_bib0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.carrev.2010.01.001","article-title":"Combination stem cell therapy for the treatment of medically refractory coronary ischemia: a phase I study","volume":"12","author":"Lasala","year":"2011","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0031","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1745-6215-14-46","article-title":"A phase II, sham-controlled, double-blinded study testing the safety and efficacy of the coronary sinus reducer in patients with refractory angina: study protocol for a randomized controlled trial","volume":"14","author":"Jolic\u0153ur","year":"2013","journal-title":"Trials"},{"key":"10.1016\/j.ahj.2024.06.001_bib0032","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199909303411403","article-title":"Comparison of transmyocardial revascularization with medical therapy in patients with refractory angina","volume":"341","author":"Allen","year":"1999","journal-title":"N Eng J Med"},{"key":"10.1016\/j.ahj.2024.06.001_bib0033","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1001\/jama.2023.0713","article-title":"Endovascular Ultrasound Renal Denervation to Treat Hypertension","volume":"329","author":"Azizi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2024.06.001_bib0034","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ejhf.676","article-title":"An exploratory randomized control study of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with ischaemic cardiomyopathy: the REGENERATE-IHD clinical trial","volume":"19","author":"Choudhury","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ahj.2024.06.001_bib0035","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0036","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/eurheartj\/ehv493","article-title":"A randomized double-blind control study of early intra-coronary autologous bone marrow cell infusion in acute myocardial infarction: the REGENERATE-AMI clinical trial","volume":"37","author":"Choudry","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0037","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1093\/eurheartj\/ehl388","article-title":"Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: Final 1-year results of the REPAIR-AMI trial","volume":"27","author":"Sch\u00e4chinger","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2024.06.001_bib0038","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.jacc.2004.08.014","article-title":"Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI trial","volume":"44","author":"Sch\u00e4chinger","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2024.06.001_bib0039","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(24)00256-3","article-title":"Coronary sinus reducer for the treatment of refractory angina (ORBITA-COSMIC): a randomised, placebo-controlled trial","volume":"403","author":"Foley","year":"2024","journal-title":"Lancet"},{"issue":"11 Suppl","key":"10.1016\/j.ahj.2024.06.001_bib0040","first-page":"S347","article-title":"A systematic review of the economic burden of chronic angina","volume":"10","author":"Reynolds","year":"2004","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.ahj.2024.06.001_bib0041","first-page":"353","article-title":"Health resource utilization and direct costs associated with angina for patients with coronary artery disease in a us managed care setting","volume":"4","author":"Kempf","year":"2011","journal-title":"Am Health Drug Benefits"},{"key":"10.1016\/j.ahj.2024.06.001_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2020.05.020","article-title":"Long-term (3 years) outcomes of ranolazine therapy for refractory angina pectoris (from the ranolazine refractory registry)","volume":"129","author":"Storey","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2024.06.001_bib0043","first-page":"CD011747","article-title":"Ranolazine for stable angina pectoris","volume":"2","author":"Salazar","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ahj.2024.06.001_bib0044","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.109.900191","article-title":"Primary Coronary Microvascular Dysfunction","volume":"121","author":"Lanza","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.06.001_bib0045","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1161\/CIRCRESAHA.119.315138","article-title":"More data than options for the \u201cno-option\u201d refractory angina patient in the United States","volume":"124","author":"Riley","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2024.06.001_bib0046","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1161\/01.CIR.0000128596.49339.05","article-title":"Therapeutic angiogenesis and vasculogenesis for ischemic disease","volume":"109","author":"Losordo","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2024.06.001_bib0047","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1161\/CIRCRESAHA.111.245993","article-title":"Intramyocardial, autologous CD34+ cell therapy for refractory angina","volume":"109","author":"Losordo","year":"2011","journal-title":"Circ Res"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870324001467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T13:34:22Z","timestamp":1732368862000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870324001467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":47,"alternative-id":["S0002870324001467"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2024.06.001","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"REGENERATE-COBRA: A phase II randomized sham-controlled trial assessing the safety and efficacy of intracoronary administration of autologous bone marrow-derived cells in patients with refractory angina","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2024.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}